Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.

Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency. Stem Cells Cloning. 2009;3:1-12 Authors: Montiel-Equihua CA, Thrasher AJ, Gaspar HB Abstract The history of stem cell gene therapy is strongly linked to the development of gene therapy for severe combined immunodeficiencies (SCID) and especially adenosine deaminase (ADA)-deficient SCID. Here we discuss the developments achieved in over two decades of clinical and laboratory research that led to the establishment of a protocol for the autologous transplant of retroviral vector-mediated gene-modified hematopoietic stem cells, which has proved to be both successful and, to date, safe. Patients in trials in three different countries have shown long-term immunological and metabolic correction. Nevertheless, improvements to the safety profile of viral vectors are underway and will undoubtedly reinforce the position of stem cell gene therapy as a treatment option for ADA-SCID. PMID: 24198507 [PubMed]
Source: Stem Cells and Cloning: Advances and Applications - Category: Stem Cells Tags: Stem Cells Cloning Source Type: research